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ABSTRACT
Objectives A pharmacy Central Intravenous 
Additives Service (CIVAS) provides ready to use 
injectable medicines. However, manipulation of 
a licensed injectable medicine may signiﬁ cantly 
alter the stability of drug(s) in the ﬁ nal product. 
The aim of this study was to develop a stability 
indicating assay for CIVAS produced dobutamine 
500 mg in 50 ml dextrose 1% (w/v) preﬁ lled 
syringes, and to allocate a suitable shelf life.
Methods A stability indicating high performance 
liquid chromatography (HPLC) assay was 
established for dobutamine. The stability of 
dobutamine preﬁ lled syringes was evaluated under 
storage conditions of 4°C (protected from light), 
room temperature (protected from light), room 
temperature (exposed to light) and 40°C (protected 
from light) at various time points (up to 42 days).
Results An HPLC method employing a 
Hypersil column, mobile phase (pH=4.0) 
consisting of 82:12:6 (v/v/v) 0.05 M 
KH2PO4:acetonitrile:methanol plus 0.3% (v/v) 
triethylamine with UV detection at λ=280 nm 
was speciﬁ c for dobutamine. Under different 
storage conditions only samples stored at 40°C 
showed greater than 5% degradation (5.08%) at 
42 days and had the shortest T95% based on this 
criterion (44.6 days compared with 111.4 days for 
4°C). Exposure to light also reduced dobutamine 
stability. Discolouration on storage was the 
limiting factor in shelf life allocation, even when 
dobutamine remained within 5% of the initial 
concentration.
Conclusions A stability indicating HPLC assay 
for dobutamine was developed. The shelf life 
recommended for the CIVAS product was 42 days 
at 4°C and 35 days at room temperature when 
protected from light.
INTRODUCTION
Dobutamine is an inotropic synthetic catecholamine 
which acts on adrenergic sympathetic receptors and is 
used to treat the majority of patients with cardiogenic 
shock at Guy’s and St Thomas’ NHS Foundation Trust 
(GSTFT). The drug is a racemic mixture of (+)-dobu-
tamine, which has strong β agonist and some α antago-
nist activity, and (−)-dobutamine which is an α agonist 
and weak β2 antagonist. The overall therapeutic effect 
of a racemic mixture of dobutamine is a blend of these 
activities. As dobutamine has a short systemic half life 
(~2 min) and is not bioavailable orally,1 it is admin-
istered as an intravenous infusion. On the hospital 
wards at GSTFT, 40 ml of concentrated dobutamine 
hydrochloride solution (12.5 mg/ml) are diluted with 
dextrose 5% (w/v) solution to a total volume of 50 
ml; this is administered using a syringe pump. This 
method of preparation is time consuming and intro-
duces risks to patient safety due to the potential for 
microbial contamination and calculation error.
Following National Patient Safety Agency alert 
20,2 the GSTFT pharmacy identiﬁ ed dobutamine 
500 mg in 50 ml infusion as one of the higher risk 
injectable medicines in use in the Trust. To manage 
this risk, dobutamine 500 mg in 50 ml of dextrose 1% 
(w/v) was selected for provision in preﬁ lled syringes 
as part of the existing pharmacy Central Intravenous 
Additives Service (CIVAS). Under CIVAS, medicines 
are prepared in the controlled environment of a phar-
macy aseptic unit and presented in ready to use form 
for administration on the ward.3 This service evolved 
as a risk management approach to avoid the risks 
associated with ward based preparation of intravenous 
additives—for example, microbial contamination, for-
mulation instability and procedural errors. The CIVAS 
approach is a well established part of hospital phar-
macy services in the UK.
The preparation of dobutamine 500 mg in 50 ml 
of dextrose 1% (w/v) dose units was initiated using a 
‘multidispensing’ model whereby licensed dobutamine 
injection concentrate was diluted to produce indi-
vidual syringes in small batches of 10 syringes. Using 
this procedure, quality control (QC) testing of drug 
content is of limited value as no unit is representative 
of the batch and these CIVAS product batches were 
released by the aseptic unit for administration without 
the standard ﬁ nal analytical QC release test for GMP 
manufactured products. Final release was based on the 
reconciliation of the licensed materials used, the prepa-
ration of the products by accredited staff and a review 
of the ﬁ nal completed batch record sheet by the qual-
ity assurance department.
When the demand for dobutamine syringes 
increased, the ‘multidispensing’ method was consid-
ered inappropriate for scale up of batch size due to 
insufﬁ cient assurance of the drug content of the ﬁ nal 
product. A production method was devised whereby 
dobutamine 10 mg/ml in dextrose 1% (w/v) was pre-
pared aseptically as a bulk solution in 6 l infusion bags 
and then transferred aseptically into syringes using a 
semiautomated pump. This method required the devel-
opment of an assay for dobutamine to: (1) evaluate the 
uniformity of mixing achieved by the manufacturing 
process, (2) verify the content of dobutamine in the 
ﬁ nal product by QC testing and (3) perform stability 
indicating studies to determine a suitable shelf life for 
the dobutamine syringes.
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There are limited published data on the chemical stability of dob-
utamine. It has been reported that the drug is rapidly broken down 
under basic conditions to form brown coloured polymers via com-
plex chemical pathways.4 Although dobutamine is stable in acidic 
conditions, it is susceptible to degradation in light.4 However, it has 
been noted that dobutamine 5 mg/ml in dextrose 5% (w/v) is stable 
in disposable 60 ml plastic syringes for 24 h at 25°C.5 Other studies 
have also reported the chemical stability of dobutamine injections 
of various concentrations under various storage conditions,6 7 but do 
not provide sufﬁ cient or relevant data on which to assign a shelf life 
for the CIVAS product. High performance liquid chromatography 
(HPLC) has also been used to demonstrate stability based on per-
centage drug remaining over 24 h when dobutamine was added to 
peritoneal dialysis solutions at ﬁ nal concentrations of 2.5, 5.0 and 
7.5 mg/ml and stored at temperatures of 4°C, 26°C and 37°C.8 
Further HPLC methods have been described for the separation and 
quantiﬁ cation of dobutamine in plasma.9 10 However, no stability 
indicating assay for dobutamine has been reported to date that satis-
ﬁ es all of the criteria required for the quality assurance/QC purposes 
described herein.
The standard for stability testing of drug products (ICH guideline 
Q1A R2) deﬁ nes a signiﬁ cant change to a drug product as: (1) a 5% 
change in assay from its initial value (the time taken for this change 
to occur is T95%); (2) appearance of any degradation product exceeding 
its acceptance criterion; and (3) failure to meet the acceptance criteria 
for appearance, physical attributes and functionality.11 We report a 
simple HPLC assay for dobutamine 500 mg in 50 ml of dextrose 1% 
(w/v) solution that is suitable for use in regular QC activity and can 
also be used as a stability indicating assay to determine T95% as part 
of the process of assigning product shelf life. The assay was used to 
verify the ﬁ tness of new manufacturing procedures and determine 
the stability of dobutamine in preﬁ lled syringes under a variety of 
storage conditions.
MATERIALS AND METHODS
Dobutamine hydrochloride reference powder was obtained from 
USP (Rockville, USA) and was used without further puriﬁ cation. 
Dobutamine hydrochloride concentrate (12.5 mg/ml; 20 ml vials) 
injections were obtained from Phoenix Pharma (Gloucester, UK); 
dextrose 5% (w/v) solution was obtained from Maco Pharma 
(Middlesex, UK) and potassium dihydrogen orthophosphate 
(KH2PO4) from Fisher Scientiﬁ c (Loughborough, UK). Dopamine, 
anisaldehyde and 4-(4-hydroxy phenyl)-2-butanone were obtained 
from Fluka (UK) while methanol, triethylamine and acetonitrile 
were obtained from Sigma-Aldrich (Dorset, UK). Becton Dickinson 
50 ml syringes were obtained from Becton Dickinson (Oxford, UK). 
All reagents used were analytical grade. A refrigerator was used to 
maintain a storage temperature of 4.0 (±1)°C. Room temperature 
was monitored throughout the period of experimentation and was 
found to have a midday value of 20.0 (±4)°C. A thermostatically 
controlled incubator was used to maintain a storage temperature of 
40.0 (±2)°C.
HPLC analysis
The Merck–Hitachi HPLC system used in the present study con-
sisted of a pump (L-6200A), ultraviolet (UV) light detector (L-400) 
and integrator (D-2500). The system was ﬁ tted with a 20 μl injec-
tion loop and separation was achieved using a HiChrom Hypersil 
octadecylsilane column (100 mm×4.5 mm×5 μm) with 10% carbon 
loading. UV studies were carried out on a calibrated Varian Cary |1| 
UV visible spectrophotometer. The isocratic ﬂ ow rate was 1.0 ml/
min and the UV detector was set at a wavelength of 280 nm.
The HPLC mobile phase consisted of 82:12:6 (v/v/v) of 0.05 M 
KH2PO4:acetonitrile:methanol plus 0.3% (v/v) triethylamine and 
was adjusted to pH 4.0 (±0.1) using phosphoric acid. The mobile 
phase solution was degassed by ﬁ ltration through a 0.45 μm nylon 
membrane followed by ultrasonication for 1 h. Standards used in 
Figure 1 A representative high performance liquid chromatography chromatogram obtained using a mixture of dopamine, dobutamine and 4-(4-hydroxyphenyl) butan-
2-one.
Table 1 Stability of dobutamine 500 mg in 50 ml syringes stored under different conditions of temperature, with and without 
exposure to light
% of initial concentration (mean ±SD, n=3)
Storage conditions 3 days 7 days 14 days 21 days 28 days 35 days 42 days
4˚C (protected from light) 100.02±0.16 99.92±0.09 99.40±0.14 99.36±0.15 99.00±0.17 98.72±0.12 98.26±0.11
Room temperature (protected from light) 99.82±0.16 99.73±0.11 99.21±0.18 98.91±0.05 98.36±0.12 97.70±0.13 97.18±0.14
40˚C (protected from light) 99.75±0.16 99.23±0.16 98.74±0.07 97.81±0.16 96.90±0.16 96.13±0.10 94.92±0.07
Room temperature (exposed to light) 99.32±0.16 99.10±0.06 98.42±0.13 98.08±0.11 97.74±0.11 97.00±0.06 96.28±0.16
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the calibration of the HPLC method were prepared by dissolving 
dobutamine hydrochloride powder in the HPLC mobile phase solu-
tion with the aid of ultrasonication. QC standards were obtained 
from a stock solution prepared by dissolving 100 mg of dobutamine 
hydrochloride powder in 10 ml of the HPLC mobile phase solution, 
producing a concentration similar to that of the CIVAS product (10 
mg/ml). Concentrations of 0.25, 0.50, 0.75, 1.00, 1.25 and 1.50 mg/
ml of dobutamine were used to establish linearity. Concentrations of 
0.25, 0.75 and 1.00 mg/ml of dobutamine were prepared by dilution 
of the stock solution by mobile phase and these were used for method 
validation (speciﬁ city, repeatability, range, precision and accuracy) 
according to ICH guidelines. Speciﬁ city was also determined by 
analysing mixtures from the accelerated degradation studies. Known 
concentrations of dobutamine were spiked into these mixtures and 
any increase in the area under the dobutamine peak was measured. 
Inter- and intra-day accuracy and precision were evaluated by analy-
sis of independent samples. Repeatability was assessed via multiple 
injections of the same standard solution. All samples were measured 
in triplicate except in the validation of method repeatability where 
10 replicates were measured.
Accelerated degradation studies
Accelerated degradation studies were conducted using dobutamine 
solution under various conditions. Decomposition of dobutamine 
under acidic conditions (0.1, 1 and 2 M HCl) was induced at 60°C 
for 72 h. Similarly, dobutamine was exposed to alkaline conditions 
of 0.1 and 1 M NaOH (at 60°C for 12 h), 3 M NaOH (room tem-
perature for 72 h) and 5 M NaOH (room temperature for 3 weeks). 
Decomposition under neutral conditions (phosphate buffer; pH 7) 
at 60°C for 72 h was also conducted. The effect of oxidative condi-
tions was studied by exposing the drug to 30% H2O2 at 60°C for 72 
h. For photostability studies, two samples were prepared in distilled 
water; one was placed at room temperature protected from light and 
the other was exposed to light for 1 week.
Stability of prefilled syringes
For stability testing, a batch of dobutamine 50 ml preﬁ lled syringes 
was manufactured in the aseptic unit at GSTFT. For the purpose of 
this study, the contents of two standard CIVAS 50 ml syringes were 
mixed and 29 samples, containing 3 ml of dobutamine solution each, 
were prepared aseptically to avoid microbiologically assisted degrada-
tion. The 3 ml samples were prepared in 50 ml syringes to match the 
packaging and storage conditions employed for the standard dobu-
tamine in dextrose product regularly manufactured at the Trust.
In the present study, four different storage conditions were inves-
tigated. Excluding the sample analysed at time zero, the remain-
ing 28 syringes were randomly divided into 4×7 syringes and each 
group was stored at 4°C protected from light, room temperature 
protected from light, room temperature in light and 40°C protected 
from light. Over the course of the study (t=0, 3, 7, 14, 21, 28, 35 
and 42 days), samples were stored in a single location with minimal 
manipulation and movement. On each day of analysis, one syringe 
was taken from each of the four groups, diluted 1 in 10 with mobile 
phase and analysed by HPLC in triplicate.
Prediction of T
95%
The degradation coefﬁ cients or rate constants (k; days−1) were deter-
mined from the slope of the plot of the log of drug remaining versus 
Figure 2 First order kinetic demonstrated by the logarithm of the dobutamine 
concentration in CIVAS syringes as a function of time, where (◆) represents 4°C 
(protected from light), (■) represents room temperature (protected from light), 
(▲) represents 40°C (protected from light) and (●) represents room temperature 
(exposed to light). Regression analysis was used to obtain the best fit; linear 
equations and their correlation coefficients are provided in table 2.
Table 2 Linear regression equation, degradation coefficient and calculated T
95%
 of dobutamine in Central Intravenous Additives 
Service syringes based on 5% loss when stored under various experimental conditions
Storage conditions
Linear regression equation and 
correlation coefficient k (days−1) Calculated T
95%
 (days)
4˚C (protected from light) y=−0.0002x+2.9995 0.000461 111.4
R2=0.9696
Room temperature (protected from light) y=−0.0003x+2.9993 0.000691 74.3
R2=0.9857
40˚C (protected from light) y=−0.0005x+2.9995 0.001152 44.6
R2=0.9901
Room temperature (exposed to light) y=−0.0004x+2.9976 0.000921 55.7
R2=0.9797
Figure 3 An Arrhenius plot demonstrating a linear correlation between the 
logarithm of the degradation coefficient (days−1) for dobutamine syringes stored 
protected from light and the inverse of temperature (y=−2201.1x+0.2338; 
R2=09897). Application of the Arrhenius equation (equation 2) allows the shelf 
life to be determined for the product stored protected from light for any given 
temperature.
14_ejhpharm-2011-000027.indd   54 2/24/2012   2:39:40 PM
 group.bmj.com on October 2, 2014 - Published by ejhp.bmj.comDownloaded from 
Research
European Journal of Hospital Pharmacy 2012;19:52–56. doi:10.1136/ejhpharm-2011-000027 55
time (days) at each of the conditions studied (room temperature was 
assigned as 22°C). The expiry date (t; days), based on a limit of 5% 
degradation, was calculated from the degradation coefﬁ cient (k) using 
equation 1:
t=2.303/k.log (Co/C) Equation 1
where Co is the initial percentage of drug at time zero (100%) and 
C is the percentage of drug remaining at time, t (95%).
An Arrhenius plot (equation 2) was constructed for samples pro-
tected from light to estimate stability at this condition at any given 
temperature:
k=Ae-Ea/RT Equation 2
where k is the rate constant, A is the pre-exponential factor, Ea is 
the activation energy, R is the gas constant and T is absolute tem-
perature in Kelvin (K).
Statistics
All values are expressed as mean±SD. Statistical evaluation of the 
data was performed with SPSS (V.15.0; SPSS, Chicago, Illinois, 
USA). Data were compared using a t test. In all cases, a difference 
was considered signiﬁ cant at p≤0.05.
RESULTS
HPLC method validation
The HPLC method was highly speciﬁ c for dobutamine, providing 
good peak resolution from the common impurities dopamine and 
4-(4-hydroxyphenyl) butan-2-one (ﬁ gure 1) and from the products 
of the stressed samples. Heating of dobutamine in acidic conditions 
produced no signiﬁ cant degradation (t test: p>0.05). In contrast, 
dobutamine was highly susceptible to oxidation under alkaline con-
ditions, forming a red/brown product. In peroxide solution at neutral 
pH, dobutamine was stable with no loss of drug or additional chro-
matographic peaks arising after 7 days. Dobutamine was sensitive 
to photodegradation with the appearance of additional peaks in the 
HPLC chromatograms following exposure to light.
Dobutamine had a retention time of approximately 7 min 
(ﬁ gure 1). Repeatability testing indicated a CV of 0.31% for 10 repli-
cates. The method was linear over the range 0.25–1.50 mg/ml with 
a correlation coefﬁ cient R2=0.9999. The limits of detection and 
quantiﬁ cation were calculated to be 0.20 and 0.94 μg/ml, respec-
tively. Intra-day and inter-day accuracy for concentrations in the lin-
ear range were acceptable (intra-day, n=6, mean deviation <0.76%; 
inter-day, n=8, mean deviation <1.18%). Precision was acceptable 
with intra-day and inter-day values for relative SD of <0.86% (n=6) 
and <0.90% (n=8), respectively.
Stability of dobutamine containing CIVAS syringes
The stability of dobutamine was dependant on the storage condi-
tions employed (table 1, ﬁ gure 2). The dobutamine concentration in 
the syringe assayed immediately postpreparation was within speci-
ﬁ cation: 0.9971±0.0031 mg/ml. The concentration of dobutamine 
in CIVAS syringes showed a progressive reduction over the storage 
period. Loss of dobutamine over the 42 day duration of the study 
remained within the <5% change in concentration limit set for this 
study for all storage conditions except for storage at 40°C where the 
loss of dobutamine was 5.08% on day 42 (table 1). The presence of 
light was shown to contribute signiﬁ cantly (t test: p<0.01) to dobu-
tamine degradation compared with storage in the absence of light. It 
was noted that some discolouration was observed in samples stored 
at 40°C in the absence of light (day 35), room temperature in the 
absence of light (day 42) and room temperature in the presence of 
light (day 28), even when dobutamine remained >95% of the ini-
tial concentration, although no quantiﬁ able degradation peaks (>10 
times the baseline noise) were observed.
Predicted T
95%
First order reaction kinetics were demonstrated by the linearity of 
the log of drug remaining versus time (ﬁ gure 2, table 2). From these 
data the degradation coefﬁ cient and the calculated T95% of dobu-
tamine syringes, based on 5% reduction in drug concentration under 
the storage conditions tested, were determined (table 2). T95% under 
the various test conditions varied from 44.6 to 111.4 days, with 
the lowest T95% when the samples were exposed to 40°C, and the 
greatest T95% at 4°C and protected from light. Construction of an 
Arrhenius plot for samples stored protected from light veriﬁ ed the 
ﬁ rst order reaction kinetics (ﬁ gure 3). The Arrhenius plot showed 
a good linear correlation (R2=0.9897) and can be used to calculate 
the T95% of dobutamine syringes stored protected from light at any 
given temperature.
DISCUSSION
Stability studies are time consuming to perform and infrequently 
undertaken for CIVAS products. However, a drug may be exposed 
to multiple chemical and physical environments as part of a 
CIVAS manufacturing process, which may result in loss of drug. 
Manipulation of drug compounds, mixing with other active/
excipient components and storage in a new container may signiﬁ -
cantly alter the stability of drug(s) in the ﬁ nal CIVAS product. This 
means that product stability cannot be inferred unequivocally from 
published stability data for the drug in the original formulations/
system(s). Thus the CIVAS system, which evolved to avoid the risks 
associated with the ward based preparation of doses for intravenous 
administration, introduces an element of uncertainty regarding the 
assurance of product quality.
Drug stability can be veriﬁ ed using stability indicating assays. 
Although several methods have been reported for the analysis of 
dobutamine stability,4–8 12–14 none of these methods reported the reso-
lution required of a stability indicating method when degraded dobu-
tamine samples were analysed. The method reported by Bishara and 
Long4 provided better separation compared with the other methods 
evaluated, but the retention time was variable and the dobutamine 
peak was frequently overlapped by the peaks of degradants. Within 
our laboratory, a HPLC method was developed that provides good 
separation of dobutamine and its degradation products using a 
mobile phase containing 0.05 M KH2PO4, acetonitrile and metha-
nol. The addition of triethylamine improved the reproducibility 
of the retention time and peak shape. Dobutamine eluted approxi-
mately midway (~7 min) through the run time in a ‘window’ with 
a stable baseline in which no breakdown product eluted, including 
all samples subjected to the forced degradation studies. Based on 
the separation achieved under normal and accelerated degradation 
studies, the method was considered a dobutamine speciﬁ c, stability 
indicating assay, as deﬁ ned by Bakshi and coworkers.15
Dobutamine is reported to be stable under acidic conditions.4 16 
Similar ﬁ ndings were observed in this study where the heating of 
dobutamine in acidic conditions produced no signiﬁ cant degrada-
tion. In contrast, dobutamine is highly susceptible to oxidation in 
alkaline conditions where the drug is converted to aminochrome at 
pH 11–13 via a free radical mediated mechanism.17 18 The amino-
chrome undergoes rapid and complex oxidation and condensation 
leading to unknown structures, including dark coloured polymers.4 
This was observable as a discolouration that was immediately 
apparent following the addition of 2 M NaOH solution to the dobu-
tamine sample. Dobutamine is also sensitive to photodegradation, 
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possibly via the formation of free radical intermediates similar to the 
mechanism described for alkaline conditions, leading to red/brown 
discolouration. Furthermore, as dobutamine is racemic, there is a 
possibility of differential enantiomer degradation, although this has 
not been studied to date and is unlikely to be of signiﬁ cance to the 
ﬁ ndings of this study.
The dobutamine content of the CIVAS syringes declined over the 
course of the study but generally remained within 5% of the initial 
concentration. Higher degradation rates occurred at higher tempera-
ture and in the presence of light but did not give rise to second-
ary chromatographic peaks nearing the limit for related substances 
described in the monograph for ‘Dobutamine intravenous infusion 
in the Ph. Eur 2010’. In addition to the loss of dobutamine measured 
by HPLC, a colour change was noted in the syringes. The syringes 
stored under light were the ﬁ rst to display a colour change, although 
no additional peaks were observed in the HPLC chromatogram. 
Discolouration of samples stored at 40°C (protected from light), 
room temperature (in the presence of light) and room temperature 
(protected from light) were observed from 35, 28 and 42 days, respec-
tively. The samples stored at 4°C and protected from light showed 
no discolouration throughout the study period. Interestingly, the 
colour produced in the absence or presence of light was different 
(brown versus pink, respectively) and a precipitate occurred in the 
samples stored protected from light only, perhaps indicating the for-
mation of different products. These changes in appearance limited 
the acceptability of the CIVAS product under these storage condi-
tions despite dobutamine concentrations remaining above the accep-
tance limit of <5% change from the initial concentration.11
CONCLUSION
The stability indicating assay for dobutamine developed in the 
present study was ﬁ t for purpose for the routine QC of CIVAS 
manufactured dobutamine syringes. Although T95% for dobutamine 
under this condition was predicted to be 111 days, stability of the 
product was limited by discolouration despite drug concentrations 
remaining >95% of label claim. When stored at 4°C protected 
from light, the dobutamine syringes were stable beyond the nomi-
nal shelf life of 28 days allocated by the CIVAS unit. The shelf life 
for dobutamine syringes stored protected from light at 4°C and 
room temperature was veriﬁ ed as 42 and 35 days, respectively; this 
being the period over which measurement was performed to sup-
port the kinetically derived stability and the absence of discoloura-
tion was conﬁ rmed.
This work enabled the validation of a cost effective batch pro-
duction process for dobutamine syringes that possess a sufﬁ cient 
shelf life at ward level. While product shelf life may be estimated 
from published data, this study provided a reliable evidence 
based measure of shelf life under a variety of storage conditions. 
Veriﬁ cation of shelf lives contributes to minimising wastage and 
provides assurance of product quality, thereby enhancing the over-
all value of the CIVAS to risk management.
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Key messages
This work enabled the validation of a cost effective batch production process 
for dobutamine syringes that possess a sufficient shelf life at ward level, and 
provided a reliable evidence based measure of shelf life under a variety of 
storage conditions.
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